Glucophage XR is a prescription medication that contains metformin as its sole active ingredient. Metformin belongs to the big-biguanide class of antidiabetic agents and is used to improve blood-sugar control in adults with type 2 diabetes. In Hong Kong, Glucophage XR is regulated by the Department of Health’s Drugs Office and is available only with a physician’s prescription. The product is supplied as an extended-release pill in a strength of 1000 mg per tablet.
Metformin primarily reduces hepatic (liver) glucose production and enhances the body’s sensitivity to insulin. By activating the enzyme AMP-activated protein kinase (AMPK), it promotes the uptake of glucose into muscle cells and decreases the amount of glucose released into the bloodstream after meals. Because the drug is released slowly over several hours, Glucophage XR provides a steadier plasma concentration, which helps maintain more consistent blood-sugar levels throughout the day. The onset of action is typically within a few days, while the full glucose-lowering effect may take 2-3 weeks to become apparent.
Glucophage XR is approved by the Hong Kong Department of Health for the treatment of type 2 diabetes mellitus in adults. It is indicated as part of a comprehensive diabetes management plan that includes diet, exercise, and, when needed, additional glucose-lowering agents. The medication is especially useful for patients who benefit from once-daily dosing and who experience gastrointestinal side effects with immediate-release metformin formulations.
Metformin has been studied for several indications beyond type 2 diabetes. When used for these purposes, it is considered off-label in Hong Kong:
Off-label use requires medical supervision and an individualized risk-benefit assessment.
Ideal candidates are adults with type 2 diabetes who need an oral glucose-lowering agent and can tolerate metformin’s gastrointestinal profile.
Special populations
If you are taking other prescription medicines, over-the-counter products, or herbal supplements, discuss them with your pharmacist before starting Glucophage XR.
Administration tips
Missed dose
Overdose
Discontinuation
Report any signs of lactic acidosis, persistent gastrointestinal distress, or unexplained weight loss to your healthcare professional promptly.
This article provides educational information about Glucophage XR and is not a substitute for professional medical advice. Treatment decisions, including the use of off-label indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Glucophage XR uses an extended-release matrix that allows the 1000 mg tablet to dissolve slowly over 8-12 hours, providing steadier blood-sugar control and often reducing gastrointestinal upset compared with immediate-release tablets that require multiple daily doses.
If your estimated glomerular filtration rate (eGFR) is between 30-45 mL/min/1.73 m², a lower starting dose and careful monitoring are recommended. Patients with eGFR < 30 mL/min/1.73 m² should not use metformin.
Yes, but keep the medication in its original packaging, carry a copy of the prescription, and be aware that some countries may require documentation for controlled substances. Store the tablets at room temperature and avoid exposure to extreme heat in luggage.
Metformin itself does not impair cognition or reaction time. However, severe hypoglycemia (rare when used alone) can affect alertness. Maintain regular glucose monitoring and follow your provider’s advice on safe driving.
Glucophage XR 1000 mg tablets are typically white, film-coated, and bear the imprint “Glucophage XR 1000”. Look for these features to confirm authenticity.
Metformin is often combined with other agents such as sulfonylureas, DPP-4 inhibitors, or insulin. Combination therapy should be prescribed and monitored by a healthcare professional to avoid hypoglycemia.
Persistent gastrointestinal symptoms may indicate the need for dose adjustment or a switch to an immediate-release formulation. Contact your prescriber before making any changes.
While some patients notice a modest reduction within a few days, the full therapeutic effect usually emerges after 2-3 weeks of consistent dosing.
Long-term metformin therapy can impair vitamin B12 absorption. Periodic B12 testing is advisable, especially if you develop neuropathic symptoms.
Metformin is generally safe in stable heart failure, but caution is required in decompensated states because reduced renal perfusion can increase the risk of lactic acidosis. A cardiologist’s assessment is recommended.